David Teachey Laboratory

Led by David Teachey, MD, this research program focuses on two areas: acute lymphoblastic leukemia and immune dysregulation. The first area of interest centers on the development and translation of novel therapies for acute lymphoblastic leukemia (ALL). The lab targets a number of signaling pathways in ALL and also develops and tests novel immunotherapies. The lab often uses xenograft models to study the efficacy of agents and mechanism of action of those agents directly on leukemia cells obtained from children.

Learn more about David Teachey Laboratory

Ongoing Research

Hematologic Malignancies Research

Ongoing Research

Clinical Use of the mTOR Pathway Inhibitor Sirolimus (rapamycin) to Treat Children with Autoimmune Lymphoproliferative Syndrome (ALPS)

Toxicity Management for Pediatric Acute Lymphoblastic leukemia (ALL) Patients Treated with Chimeric Antigen Receptor (CAR) T-cells

Selected Publications

Bride K, Vincent T, Smith-Whitley K, Lambert MP, Bleesing J, Seif AE, Manno CS, Casper J, Grupp SA, and Teachey DT. (2016). Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 127(1): 17-28. (Plenary Paper). PMID 26504182

Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J. Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, and Grupp SA. (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discovery. 6(6):664-79. PMID. 27076371

Teachey DT and Pui CH. (2019) Comparative features and outcome between pediatric T- and B- acute lymphoblastic leukemia. Lancet Oncol. 20(3): e142-154. PMID: 30842058